Leadership
Pipeline
Pipeline Overview
Ciprocopan (NXP100)
NXP200
NXP900
Clinical Trials
Publications
Investors & News
Investor Relations Overview
Press Releases
Stock Information
SEC Filings
Events & Presentations
Governance Documents
Email Alerts
Contact
Careers
Email Alerts
Leadership
Pipeline
Pipeline Overview
Ciprocopan (NXP100)
NXP200
NXP900
Clinical Trials
Publications
Investors & News
Investor Relations Overview
Press Releases
Stock Information
SEC Filings
Events & Presentations
Governance Documents
Email Alerts
Contact
Careers
Email Alerts
Contact Us
Disclaimer
Email Alerts
Governance Documents
Home
Investor Relations
Leadership
Ciprocopan (NXP100): Complement Factor B Inhibitor
NXP200: Paradox Breaker BRAF Inhibitor
NXP900: SRC/YES1 Kinase Inhibitor
Pipeline
Events & Presentations
Press Releases
Privacy Policy
Publications
SEC Filings
Stock Quote
Terms of Use
Clinical Trials
Careers
Press Releases
Overview
Press Releases
Stock Information
SEC Filings
Events & Presentations
Governance Documents
Email Alerts
Press Releases
Press Release
Loading press release…
Enable JavaScript to load this release, or visit the
press release archive
.
More press releases
OCT 09, 2026
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
SEP 24, 2026
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
SEP 03, 2026
Nuvectis Pharma To Participate in Upcoming Investor Conferences
